Example: Heart Attack

Clinical Trials on Neoplasms, Mesothelial

Total 394 results





    • NCT02004028
      Terminated
      Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
      Conditions: Malignant Pleural Mesothelioma
    • NCT01552434
      Recruiting
      Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
      Conditions: Advanced Malignant Neoplasm; Castleman Disease; Digestive System Carcinoma; Erdheim-Chester Disease; Lip and Oral Cavity Carcinoma; Lymphangioleiomyomatosis; Malignant Endocrine Neoplasm; Malignant Female Reproductive System Neoplasm; Malignant Male Reproductive System Neoplasm; Malignant Neoplasm; Malignant Respiratory Tract Neoplasm; Malignant Thoracic Neoplasm; Malignant Urinary System Neoplasm; Mesothelial Neoplasm; Metastatic Malignant Neoplasm; Metastatic Urothelial Carcinoma; Neurofibromatosis Type 2; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Digestive System Carcinoma; Recurrent Female Reproductive System Carcinoma; Recurrent Male Reproductive System Carcinoma; Recurrent Malignant Neoplasm; Recurrent Pharyngeal Carcinoma; Recurrent Thyroid Gland Carcinoma; Refractory Malignant Neoplasm; Soft Tissue Neoplasm; Stage III Breast Cancer AJCC v7; Stage III Pharyngeal Cancer; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Pharyngeal Cancer; Stage IVA Pharyngeal Cancer; Stage IVB Pharyngeal Cancer; Stage IVC Pharyngeal Cancer; Thyroid Gland Neoplasm
    • NCT01655225
      Active, not recruiting
      A Study of LY3023414 in Participants With Advanced Cancer
      Conditions: Advanced Cancer; Metastatic Cancer; Non-Hodgkin's Lymphoma; Metastatic Breast Cancer; Malignant Mesothelioma; Non-small Cell Lung Cancer
    • NCT04489862
      Recruiting
      αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
      Conditions: Non-small-cell Lung Cancer; Mesothelioma
    • NCT04042480
      Recruiting
      A Study of SGN-CD228A in Advanced Solid Tumors
      Conditions: Cutaneous Melanoma; Pleural Mesothelioma; Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Ductal Adenocarcinoma
    • NCT03917043
      Recruiting
      APG-2449 in Patients With Advanced Solid Tumors
      Conditions: Advanced Solid Cancer; Non Small Cell Lung Cancer; Esophageal Cancer; Ovarian Cancer; Malignant Pleural Mesothelioma
    • NCT03852823
      Recruiting
      Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
      Conditions: Advanced Solid Tumours; Cervical Cancer; Malignant Mesothelioma; Lymphoma; Non-Small-Cell Lung Cancer
    • NCT04316689
      Recruiting
      First-in-human Study of S-588210 (S-488210+S-488211)
      Conditions: Lung Cancer; Head and Neck Cancer; Bladder Cancer; Esophageal Cancer; Mesothelioma
    • NCT03507452
      Recruiting
      First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
      Conditions: Advanced Recurrent Epithelioid Mesothelioma; Serous Ovarian Cancer; Metastatic or Locally Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion)
    • NCT02639091
      Completed
      Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
      Conditions: Medical Oncology
    • NCT02214134
      Unknown status
      SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
      Conditions: Any Stage of Lung Cancer (Any Histotype); Any Stage of Malignant Pleural Mesothelioma; Any Stage of Any Thymic Malignancy
    • NCT02948413
      Completed
      Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials
      Conditions: Lymphoma; Mesothelioma; Prostate Cancer; Leukemia
    • NCT03558932
      Not yet recruiting
      IP3R Modulation by Cancer Genes in Mesothelioma
      Conditions: Malignant Mesothelioma
    • NCT04429204
      Not yet recruiting
      Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma
      Conditions: Mesothelioma
    • NCT03537833
      Recruiting
      Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed
      Conditions: Patients With Non-small Cell Lung Cancer (NSCLC) and Pleural Mesothelioma and Treated With a Pemetrexed-based Chemotherapy
    • NCT04515836
      Not yet recruiting
      Olaparib in Patients With HRD Malignant Mesothelioma
      Conditions: Mesothelioma; Homologous Recombination Deficiency
    • NCT03610360
      Recruiting
      DENdritic Cell Immunotherapy for Mesothelioma
      Conditions: Mesothelioma
    • NCT03502746
      Recruiting
      Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
      Conditions: Mesothelioma, Malignant
    • NCT04577326
      Recruiting
      Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
      Conditions: Malignant Pleural Mesothelioma (MPM)
    • NCT04525859
      Recruiting
      Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
      Conditions: Malignant Pleural Mesothelioma
    • NCT04481672
      Not yet recruiting
      Intravenous Magnesium in Patients Receiving Cisplatin
      Conditions: Mesothelioma
    • NCT04462809
      Not yet recruiting
      Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma
      Conditions: Advanced Malignant Pleural or Peritoneal Mesothelioma
    • NCT04400539
      Not yet recruiting
      The IMmunotherapy Pleural 5-ALA PDT
      Conditions: Mesotheliomas Pleural; Malignant Pleural Mesothelioma
    • NCT04334759
      Not yet recruiting
      DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
      Conditions: Mesothelioma; Pleural Mesothelioma; Malignant Pleural Mesothelioma
    • NCT04287829
      Not yet recruiting
      Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
      Conditions: Mesotheliomas Pleural
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations